Progression of paclitaxel in the chemotherapy of advanced esophageal cancer
10.3760/cma.j.issn.1006-9801.2011.10.028
- VernacularTitle:紫杉醇在晚期食管癌治疗中的研究进展
- Author:
Yan YING
;
Hu BING
- Publication Type:Journal Article
- Keywords:
Paclitaxel;
Esophageal neoplasms;
Therapy
- From:
Cancer Research and Clinic
2011;23(10):715-718
- CountryChina
- Language:Chinese
-
Abstract:
Recently,paclitaxel has been used as a new agent on patients with advanced esophageal cancer,and several studies have demonstrated that paclitaxel and paclitaxel-based regimens have significant activity in patients with advanced esophageal cancer and showed highly response rates than the combination of 5-fluorouracil (5-Fu) and cisplatin.However,there have been some problems which need to be solved such as drug-resistance,side effect,and so forth.The new medicament form of paclitaxel can not only depress poison without anti-allergy but also raise medicament curative effect as well as the pharmacal concentration.Although most of the research on the new medicament form of paclitaxel are still limited in the stage of laboratory,it has possessed potential advance in the treatment of advanced esophageal cancer.
